Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) EBT Margin (2022 - 2025)

Dianthus Therapeutics has reported EBT Margin over the past 4 years, most recently at 9833.59% for Q3 2025.

  • Quarterly results put EBT Margin at 9833.59% for Q3 2025, down 855384.0% from a year ago — trailing twelve months through Sep 2025 was 4142.07% (down 276731.0% YoY), and the annual figure for FY2024 was 1355.24%, up 18086.0%.
  • EBT Margin for Q3 2025 was 9833.59% at Dianthus Therapeutics, up from 17886.53% in the prior quarter.
  • Over the last five years, EBT Margin for DNTH hit a ceiling of 2435.92% in Q4 2022 and a floor of 17886.53% in Q2 2025.
  • Median EBT Margin over the past 4 years was 1594.37% (2023), compared with a mean of 3122.9%.
  • Biggest five-year swings in EBT Margin: skyrocketed 118648bps in 2024 and later tumbled -1692475bps in 2025.
  • Dianthus Therapeutics' EBT Margin stood at 2435.92% in 2022, then plummeted by -225bps to 3045.08% in 2023, then skyrocketed by 39bps to 1858.6% in 2024, then crashed by -429bps to 9833.59% in 2025.
  • The last three reported values for EBT Margin were 9833.59% (Q3 2025), 17886.53% (Q2 2025), and 2526.74% (Q1 2025) per Business Quant data.